In Plain English
Growth hormone does several different things, and researchers hoped they could isolate just the fat-burning part by using only the tail end of the molecule. The theory was elegant: get the fat loss, skip the effects on blood sugar and tissue growth. It was tested properly in people. The tolerability held up; the fat loss did not.
What people use it for. Fat loss, on the theory that it isolates the fat-burning part of growth hormone without the rest.
What to know before you buy. We would rather tell you this than have you find out later: AOD-9604 was tested properly in placebo-controlled human obesity trials, and it did not beat placebo on weight loss. That is unusual in this category, where most compounds have never been tested at all — and it cuts both ways, because it also means the safety data is better than most. It was well tolerated and did not disturb blood sugar or IGF-1. If you want it for tolerability or for the newer joint and cartilage research, that is a defensible reason. If you want it for fat loss, the trial record does not support that.
What It's Used For
| Goal | What that rests on |
|---|---|
| Favourable tolerability | Well tolerated in human trials, with no significant effect on IGF-1 or blood glucose |
| Joint and cartilage research | A newer and still early line of investigation |
| Honest caveat | In placebo-controlled human obesity trials it did not produce significant weight loss versus placebo. We would rather tell you now |
The left column lists goals people commonly pursue with this compound; the right column states what that rests on. These are described uses and research findings, not proven outcomes or treatment claims. Individual results vary and no outcome is promised.
Pricing & Sizes
Ships sealed and lyophilized — stable for years at room temperature, reconstitute before use, or ask and it will be reconstituted free at the volume shown below. Free shipping on every order, no minimum. Third-party COA available for every batch — HPLC purity and mass spec verification.
Reconstitution — bacteriostatic water: 5mg vial at 2mL = 2.5mg/mL, so 10 units on a 100-unit syringe draws 0.25mg. Concentrations are arithmetic from vial content and diluent volume, not a dosing recommendation.
Text To OrderAt a Glance
- Class
- Synthetic peptide corresponding to the C-terminal fragment (residues 176-191) of human growth hormone
- Original rationale
- Proposed to carry hGH’s fat-metabolising activity without its growth-promoting or glucose effects
- Clinical testing
- Developed through phase II for obesity by Metabolic Pharmaceuticals
- Outcome
- Did not demonstrate significant weight loss versus placebo on the primary endpoint; the obesity development programme did not proceed to approval
- Safety signal
- Generally well tolerated in the trials, with no significant effect on IGF-1 or glucose
- Regulatory (US)
- Not FDA-approved. Not on the July 2026 PCAC agenda
- Format
- 5mg vial
Evidence status — read this first
AOD-9604 is one of the few compounds in this category to have completed proper placebo-controlled human obesity trials. It did not produce statistically significant weight loss versus placebo on the primary endpoint, and the obesity programme did not advance to approval. Marketing that presents AOD-9604 as a proven fat-loss compound is not consistent with its own trial record. It was not on the July 2026 PCAC agenda.
What the Trials Showed
The development programme took AOD-9604 through phase II in obesity. The trials achieved something most compounds here never attempt: a real placebo-controlled test of the central claim. The headline result was that the compound did not separate meaningfully from placebo on weight reduction.
The safety findings were genuinely favourable. AOD-9604 did not produce the IGF-1 elevation or glucose effects associated with full-length growth hormone, which is consistent with the design rationale — the fragment does appear to avoid those effects. It simply also appears to avoid producing the intended one at a clinically meaningful level.
Why it remains on the market
Interest persisted partly on the strength of preclinical work and partly through subsequent attention to other possible applications, including cartilage and joint research. Those lines are early and are not the basis on which the compound is usually sold. Its favourable tolerability profile also keeps it in circulation.
The bottom line
A well-designed idea that was properly tested and did not deliver on its primary endpoint. Reliable tolerability, no demonstrated fat-loss efficacy versus placebo. Of everything in this range, AOD-9604 is the compound where the honest evidence summary differs most sharply from the typical sales pitch.
Also in the Range
Compare with Tirzepatide and Retatrutide for fat loss, both of which have demonstrated weight reduction in controlled trials where AOD-9604 did not.